Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Diltiazem Protocol for AF in ED
NCT05391893Phase 4Completed
- Sponsor
- Corewell Health
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of diltiazem in Atrial fibrillation (AFib) and atrial flutter (AFL) (2 arms), sponsored by Corewell Health. Primary endpoints: Admission Rate at 1 day and Treatment Success at 3 Hours. Started Jun 2020; status: completed.
02
Drugs
diltiazem
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT05391893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05391893.